Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients

Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramanian, Subbaya, Iles, Tinen, Ikramuddin, Sayeed, Steer, Clifford J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350268/
https://www.ncbi.nlm.nih.gov/pubmed/32575350
http://dx.doi.org/10.3390/vaccines8020320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350268/
https://www.ncbi.nlm.nih.gov/pubmed/32575350
http://dx.doi.org/10.3390/vaccines8020320

Ejemplares similares